B001 for NMOSD: reducing relapses
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD (neuromyelitis optica spectrum disorder).
- You have had at least 1 relapse in the past year, or at least 2 relapses in the past 2 years.
- You are not pregnant or breastfeeding, and you agree to use birth control during the study and for 6 months after.
- You have not received certain treatments (like anti-CD20 drugs) in the last 6 months.
- You are willing to follow the study plan and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called NouvSoma001 for neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the optic nerves and spinal cord. It looks at whether the drug is safe and helps people who have had a recent attack with severe pain, trouble walking, or bladder/bowel problems.
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
Hear when a new Neuromyelitis Optica Spectrum Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.